VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
RMD
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
RMDResMed Inc.
$219.75$32.0B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

RMD logoResMed Inc.(RMD)Earnings, Financials & Key Ratios

RMD•NYSE
$219.75
23.1× P/E·Price updated Jul 7, 2026
SectorHealthcareIndustryMedical InstrumentsSub-IndustryPatient monitoring and respiratory care
AboutResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.Show more
  • Revenue$5.15B+9.8%
  • EBITDA$1.92B+25.1%
  • Net Income$1.4B+37.2%
  • EPS (Diluted)9.51+37.4%
  • Gross Margin59.36%+4.7%
  • EBITDA Margin37.33%+13.9%
  • Operating Margin32.75%+16.3%
  • Net Margin27.22%+24.9%
  • ROE25.86%+13.9%

RMD Price & Volume

ResMed Inc. (RMD) stock price & volume — 10-year historical chart

Loading chart...

ResMed Demonstrates Structural Margin Expansion and Resilience

Investment Thesis • Updated 2026Q3

VerdictPositive
Growth:Stable
Profitability:Strong
Financial:Fortress
Cash Flow:Robust
Primary Risk:Competitive Re-entry and Reimbursement

Key Thesis Takeaways

  • ResMed exhibits a compelling fundamental profile characterized by consistent revenue growth and significant margin expansion, as evidenced by a 62.2% gross margin in 2026Q3.
  • The company's transition toward a digital-first, low-capital-intensity model supports robust free cash flow generation, though investors should monitor the $3.5 billion goodwill concentration and potential competitive pricing pressures.
  • A disciplined capital allocation strategy, highlighted by $175.0 million in quarterly share repurchases, further reinforces the firm's long-term value proposition.

Verdict Logic

the company's ability to maintain a 34.9% operating margin while sustaining a 1.1% dividend yield and aggressive buyback program suggests a high-quality, resilient investment opportunity.

RMD Growth Metrics

ResMed Inc. (RMD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years11.85%
5 Years11.72%
3 Years12.88%
TTM10.28%

Profit CAGR

10 Years14.78%
5 Years17.64%
3 Years21.58%
TTM15.71%

EPS CAGR

10 Years14.43%
5 Years17.37%
3 Years21.52%
TTM16.05%

Return on Capital

10 Years21.04%
5 Years23.41%
3 Years23.18%
Last Year25.7%

RMD Recent Earnings

ResMed Inc. (RMD) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
Apr 30, 2026
Metric
Actual
Est
EPS
$2.86+2.1%
$2.80
Rev
$1.4B+0.8%
$1.4B
Q1 2026
Jan 29, 2026
Metric
Actual
Est
EPS
$2.81+2.6%
$2.74
Rev
$1.4B+1.6%
$1.4B
Q4 2025
Oct 30, 2025
Metric
Actual
Est
EPS
$2.55+1.6%
$2.51
Rev
$1.3B+0.2%
$1.3B
Q3 2025
Jul 31, 2025
Metric
Actual
Est
EPS
$2.55+0.0%
$2.55
Rev
$1.3B+0.0%
$1.3B
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestApr 30, 2026
$2.86vs $2.80+2.1%
$1.4Bvs $1.4B+0.8%
Q1 2026Jan 29, 2026
$2.81vs $2.74+2.6%
$1.4Bvs $1.4B+1.6%
Q4 2025Oct 30, 2025
$2.55vs $2.51+1.6%
$1.3Bvs $1.3B+0.2%
Q3 2025Jul 31, 2025
$2.55vs $2.55+0.0%
$1.3Bvs $1.3B+0.0%
Based on last 12 quarters of dataView full earnings history →

Latest RMD News

Recent stock market news and headlines for ResMed Inc. (RMD)

GlobeNewsWire·13h ago
Resmed Announces Agreement to Sell MatrixCare Business

SAN DIEGO, July 07, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has entered into a definitive agreement to sell its MatrixCare business to Frazier Healthcare Partners, a private equity firm focused exclusively on health care. This move reflects Resmed's 2030 strategy by focusing on high-growth, scalable opportunities in sleep health, breathing health and connected home-based healthcare.

Zacks Investment Research·17h ago
Will ResMed (RMD) Beat Estimates Again in Its Next Earnings Report?

ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Investment Research·18h ago
ResMed (RMD) Soars 4.2%: Is Further Upside Left in the Stock?

ResMed (RMD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Investment Research·19h ago
Here's Why ResMed (RMD) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research·6 days ago
ResMed (RMD) Upgraded to Buy: Here's Why

ResMed (RMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Peers Comparison

Key metrics vs top competitors for ResMed Inc. (RMD)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
RMD logoRMDResMed Inc.Current
$219.75$32.01B23.119.84%27.22%25.86%0.96%
PHG logoPHGKoninklijke Philips N.V.
$28.23$26.88B26.56-1.04%5.49%8.96%—
ITGR logoITGRInteger Holdings Corporation
$91.90$3.16B31.807.57%7.67%8.23%—
NVCR logoNVCRNovoCure Limited
$17.72$2.02B-14.528.28%-25.66%-50.82%—
INSP logoINSPInspire Medical Systems, Inc.
$50.08$1.44B10.2413.6%14.33%17.98%—
TNDM logoTNDMTandem Diabetes Care, Inc.
$15.43$1.06B-5.087.93%-9.2%-68.29%—

Compare RMD vs Peers

ResMed Inc. (RMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs PHG

Most directly comparable listed peer for RMD.

Scale Benchmark

vs AMZN

Larger-name benchmark to compare RMD against a more recognizable public peer.

Peer Set

Compare Top 5

vs PHG, ITGR, NVCR, INSP

RMD SEC Filings & Documents

ResMed Inc. (RMD) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Apr 30, 2026·SEC

Material company update

Apr 30, 2026·SEC

Material company update

Jan 29, 2026·SEC

10-K Annual Reports

2
FY 2025

Aug 8, 2025·SEC

FY 2024

Aug 9, 2024·SEC

10-Q Quarterly Reports

4
FY 2026

Jan 30, 2026·SEC

FY 2025

Oct 31, 2025·SEC

FY 2025

Jan 31, 2025·SEC

Get notified when RMD posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

RMD Frequently Asked Questions

ResMed Inc. (RMD) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is ResMed Inc.'s revenue?

ResMed Inc. (RMD) reported $5.54B in revenue for fiscal year 2025. This represents a 15905% increase from $34.6M in 1996.

How fast is ResMed Inc. growing?

ResMed Inc. (RMD) grew revenue by 9.8% over the past year. This is steady growth.

Is RMD profitable?

Yes, ResMed Inc. (RMD) is profitable, generating $1.52B in net income for fiscal year 2025 (27.2% net margin).

Dividend & Returns
Does RMD pay dividends?

Yes, ResMed Inc. (RMD) pays a dividend with a yield of 0.96%. This makes it attractive for income-focused investors.

What is RMD's return on equity?

ResMed Inc. (RMD) has a return on equity (ROE) of 25.9%. This is excellent, indicating efficient use of shareholder capital.

What is ResMed Inc.'s free cash flow?

ResMed Inc. (RMD) generated $1.75B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in RMD back in 1996?

Total return calculator · dividends reinvested · 30+ years of data

See returns →